$237 Million is the total value of Fairmount Funds Management LLC's 21 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 38.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INSM | INSMED INC | $32,759,000 | +2.3% | 961,797 | 0.0% | 13.81% | +20.6% | |
| ZGNX | Buy | ZOGENIX INC | $27,431,000 | +39.9% | 1,405,259 | +43.3% | 11.56% | +64.9% |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $17,916,000 | -31.8% | 565,890 | 0.0% | 7.55% | -19.6% | |
| ALLK | ALLAKOS INC | $16,949,000 | -18.0% | 147,662 | 0.0% | 7.14% | -3.4% | |
| AXSM | Buy | AXSOME THERAPEUTICS INC | $14,245,000 | -20.6% | 251,598 | +14.3% | 6.00% | -6.4% |
| Sell | TRILLIUM THERAPEUTICS INC | $14,211,000 | -34.6% | 1,323,181 | -10.5% | 5.99% | -23.0% | |
| ARGX | Buy | ARGENX SEsponsored adr | $14,169,000 | -3.5% | 51,450 | +3.0% | 5.97% | +13.7% |
| TIL | New | INSTIL BIO INC | $13,794,000 | – | 550,000 | +100.0% | 5.81% | – |
| COGT | COGENT BIOSCIENCES INC | $13,688,000 | -21.8% | 1,558,975 | 0.0% | 5.77% | -7.8% | |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $11,614,000 | -12.6% | 67,800 | +12.1% | 4.90% | +3.0% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $11,154,000 | -53.7% | 432,317 | -4.0% | 4.70% | -45.4% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $9,987,000 | +35.4% | 1,608,237 | +6.6% | 4.21% | +59.6% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $8,441,000 | +33.3% | 171,147 | +13.8% | 3.56% | +57.1% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $7,795,000 | -74.3% | 788,980 | -40.0% | 3.29% | -69.8% |
| MCRB | Buy | SERES THERAPEUTICS INC | $7,269,000 | +15.4% | 353,016 | +37.4% | 3.06% | +36.1% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $7,131,000 | -23.4% | 175,000 | -18.6% | 3.01% | -9.7% |
| KROS | New | KEROS THERAPEUTICS INC | $6,729,000 | – | 109,333 | +100.0% | 2.84% | – |
| VRNA | Sell | VERONA PHARMA PLCsponsored ads | $702,000 | +0.3% | 83,944 | -16.1% | 0.30% | +18.4% |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $581,000 | – | 35,092 | +100.0% | 0.24% | – |
| RACA | New | THERAPEUTICS ACQUISITION COR | $526,000 | – | 50,000 | +100.0% | 0.22% | – |
| New | CATABASIS PHARMACEUTICALS IN | $154,000 | – | 53,166 | +100.0% | 0.06% | – | |
| MGEN | Exit | MIRAGEN THERAPEUTICS INC | $0 | – | -35,092 | -100.0% | -0.20% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -702,351 | -100.0% | -3.89% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.